Osamu Hataji

2.1k total citations
73 papers, 1.2k citations indexed

About

Osamu Hataji is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Osamu Hataji has authored 73 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 59 papers in Pulmonary and Respiratory Medicine, 33 papers in Oncology and 10 papers in Physiology. Recurrent topics in Osamu Hataji's work include Lung Cancer Treatments and Mutations (31 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (14 papers) and Lung Cancer Research Studies (14 papers). Osamu Hataji is often cited by papers focused on Lung Cancer Treatments and Mutations (31 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (14 papers) and Lung Cancer Research Studies (14 papers). Osamu Hataji collaborates with scholars based in Japan, United States and Sweden. Osamu Hataji's co-authors include Osamu Taguchi, Esteban C. Gabazza, Yukihiko Adachi, Tetsu Kobayashi, Hisamichi Yuda, Kentaro Ito, Koichiro Yamakado, Atsuhiro Nakatsuka, Hajime Fujimoto and Kan Takeda and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Scientific Reports.

In The Last Decade

Osamu Hataji

66 papers receiving 1.2k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Osamu Hataji Japan	17	734	281	233	205	143	73	1.2k
Raoul Bergner Germany	19	352 0.5×	347 1.2×	202 0.9×	103 0.5×	171 1.2×	80	1.1k
Joseph Weisstuch United States	7	319 0.4×	188 0.7×	65 0.3×	124 0.6×	344 2.4×	8	1.3k
Terenig Terjanian United States	10	182 0.2×	490 1.7×	39 0.2×	188 0.9×	126 0.9×	30	935
Takashi Inoue Japan	19	440 0.6×	383 1.4×	85 0.4×	41 0.2×	62 0.4×	129	1.3k
Masahiro Ieko Japan	23	259 0.4×	101 0.4×	86 0.4×	815 4.0×	142 1.0×	117	1.7k
Dimitrios A. Pappas United States	19	181 0.2×	100 0.4×	123 0.5×	234 1.1×	96 0.7×	87	1.3k
Leila A. Kutteh United States	14	117 0.2×	634 2.3×	128 0.5×	177 0.9×	154 1.1×	23	995
Noriko Hayami Japan	22	337 0.5×	153 0.5×	85 0.4×	118 0.6×	355 2.5×	134	1.5k
Grégoire Prévôt France	18	1.3k 1.8×	158 0.6×	205 0.9×	18 0.1×	118 0.8×	72	1.7k

Countries citing papers authored by Osamu Hataji

Since Specialization

Citations

This map shows the geographic impact of Osamu Hataji's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Osamu Hataji with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Osamu Hataji more than expected).

Fields of papers citing papers by Osamu Hataji

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Osamu Hataji. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Osamu Hataji. The network helps show where Osamu Hataji may publish in the future.

Co-authorship network of co-authors of Osamu Hataji

This figure shows the co-authorship network connecting the top 25 collaborators of Osamu Hataji. A scholar is included among the top collaborators of Osamu Hataji based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Osamu Hataji. Osamu Hataji is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yatera, Kazuhiro, Zhang Wang, Yoko Shibata, et al.. (2025). Sputum Microbiome, Potentially Pathogenic Organisms, and Clinical Outcomes in Japanese Patients with COPD and Moderate Airflow Limitation: The Prospective AERIS-J Study. International Journal of COPD. Volume 20. 1477–1492.

Sakaguchi, Tadashi, et al.. (2023). A case of tracheal stenosis due to anaplastic thyroid carcinoma treated using the stent‐in‐stent method. Thoracic Cancer. 15(4). 350–352. 1 indexed citations

Nishii, Yoichi, Tadashi Sakaguchi, Yuki Nakamura, et al.. (2023). Close-to-lesion transbronchial biopsy: a novel technique to improve suitability of specimens for genetic testing in patients with peripheral pulmonary lesions. Scientific Reports. 13(1). 14724–14724. 3 indexed citations

Ito, Atsushi, Yūta Suzuki, Tadashi Sakaguchi, et al.. (2023). Clinicopathological and Molecular Characteristics Promoting PD-L1 Expression in Early-stage Lung Adenocarcinoma and Squamous Cell Carcinoma. Anticancer Research. 43(11). 5197–5204. 1 indexed citations

Jones, Paul, Osamu Hataji, Yoshimi Suzukamo, et al.. (2023). Development of a Communication Tool between Patients and Physicians for Recognizing COPD Exacerbations in Japan. COPD Journal of Chronic Obstructive Pulmonary Disease. 20(1). 216–223. 3 indexed citations

Sakaguchi, Tadashi, Yasumasa Kokubo, Kazuki Furuhashi, et al.. (2021). An Extensive-stage Small-cell Lung Cancer Case With Preexisting Lambert-Eaton Myasthenic Syndrome Successfully Treated With an Immune Checkpoint Inhibitor. Clinical Lung Cancer. 23(3). e273–e275. 8 indexed citations

Ito, Kentaro, Masahiro Morise, Kazushige Wakuda, et al.. (2021). A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903. ESMO Open. 6(3). 100115–100115. 33 indexed citations

Hayashi, Hidetoshi, Kimio Yonesaka, Shunichi Sugawara, et al.. (2021). FP14.16 Phase 2 Trial of the Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non–Small Cell Lung Cancer (WJOG10818L/Alt Trial). Journal of Thoracic Oncology. 16(3). S234–S235. 1 indexed citations

Kozuki, Toshiyuki, Naoyuki Nogami, Osamu Hataji, et al.. (2020). Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323. Translational Lung Cancer Research. 9(3). 459–470. 4 indexed citations

10.

Ichinose, Masakazu, Yasushi Fukushima, Yoshikazu Inoue, et al.. (2019). <p>Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD</p>. International Journal of COPD. Volume 14. 2993–3002. 14 indexed citations

11.

Ichinose, Masakazu, Yasushi Fukushima, Yoshikazu Inoue, et al.. (2019). <p>Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study</p>. International Journal of COPD. Volume 14. 2979–2991. 12 indexed citations

12.

Nakamura, Yuki, Tetsu Kobayashi, Yoichi Nishii, et al.. (2018). Comparable immunoreactivity rates of PD‐L1 in archival and recent specimens from non‐small cell lung cancer. Thoracic Cancer. 9(11). 1476–1482. 7 indexed citations

13.

Ito, Kentaro, Osamu Hataji, Hiroyasu Kobayashi, et al.. (2016). Sequential Therapy with Crizotinib and Alectinib in ALK -Rearranged Non–Small Cell Lung Cancer—A Multicenter Retrospective Study. Journal of Thoracic Oncology. 12(2). 390–396. 35 indexed citations

14.

Naito, Masahiro, Osamu Taguchi, Tetsu Kobayashi, et al.. (2013). Thrombin-Activatable Fibrinolysis Inhibitor Protects against Acute Lung Injury by Inhibiting the Complement System. American Journal of Respiratory Cell and Molecular Biology. 49(4). 646–653. 23 indexed citations

15.

Akeboshi, Masao, Koichiro Yamakado, Atsuhiro Nakatsuka, et al.. (2004). Percutaneous Radiofrequency Ablation of Lung Neoplasms: Initial Therapeutic Response. Journal of Vascular and Interventional Radiology. 15(5). 463–470. 173 indexed citations

16.

Hataji, Osamu, Osamu Taguchi, Esteban C. Gabazza, et al.. (2004). Increased circulating levels of thrombin‐activatable fibrinolysis inhibitor in lung cancer patients. American Journal of Hematology. 76(3). 214–219. 38 indexed citations

17.

Fujimoto, Hajime, Esteban C. Gabazza, Osamu Hataji, et al.. (2003). Thrombin-activatable Fibrinolysis Inhibitor and Protein C Inhibitor in Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 167(12). 1687–1694. 36 indexed citations

18.

Kobayashi, Tetsu, Esteban C. Gabazza, Shino Shimizu, et al.. (2001). Long-term Inhalation of High-dose Nitric Oxide Increases Intraalveolar Activation of Coagulation System in Mice. American Journal of Respiratory and Critical Care Medicine. 163(7). 1676–1682. 10 indexed citations

19.

Yasui, Hiroki, Esteban C. Gabazza, Shigenori Tamaki, et al.. (2001). Intratracheal Administration of Activated Protein C Inhibits Bleomycin-induced Lung Fibrosis in the Mouse. American Journal of Respiratory and Critical Care Medicine. 163(7). 1660–1668. 116 indexed citations

20.

Kobayashi, Hiroyasu, Esteban C. Gabazza, Osamu Taguchi, et al.. (1998). Protein C Anticoagulant System in Patients with Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine. 157(6). 1850–1854. 57 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact